报告主题：Biomedical Engineering Solutions for Patient Therapy Using AdvancedBiomaterials
The member of the National Academy of Engineering
National Academy of Medicine and National Academy of Inventors, USA
The member of American Academy of Arts Sciences
Nicholas A. Peppas is the Cockrell Family Regents Chaired Professor in theDepartments of Chemical, Biomedical Engineering, Surgery and Pharmacy, andDirector of the Institute of Biomaterials, Drug Delivery and RegenerativeMedicine of the University of Texas at Austin.His work in biomaterials, polymer physics, drug delivery andbionanotechnology follows a multidisciplinary approach by blending modern molecularand cellular biology with engineering principles to design the next-generationof medical systems and devices for patient treatment. Over the past 40 years hehas set the fundamentals and rational design of drug delivery systemsand developed models of drug and proteindiffusion in controlled release devices and biological tissues. In 2012 hereceived the Founders Award of the National Academy of Engineering (NAE), thehighest recognition of the Academy, for these contributions to the field.Peppas is a member of the NAE, National Academy of Medicine, National Academyof Inventors, the National Academy of France, the Royal Academy of Spain, theAcademy of Athens and the Academy of Texas.He has been recognized with awards from AIChE (Founders Award, WilliamWalker Award, Institute Lecture, Jay Bailey Award, Bioengineering Award,Materials Award), the Biomedical Engineering Society (Distinguished ScientistAward), the American Institute of Medical and Biological Engineering (GallettiAward), the Society for Biomaterials (Founders, Clemson and Hall Awards), theControlled Release Society (Founders, Heller and Eurand Awards) and othersocieties. In 2008, AIChE named him on of the One Hundred Chemical Engineers ofthe Modern Era. He is President of the International Union of Societies of BiomaterialsScience and Engineering, Chair of the Engineering Section of the AmericanAssociation for the Advancement of Science, and Past-Chair of the Council ofBME Chairs. Previously, he served as President of SFB and the ControlledRelease Society.He is a fellow of AAAS,AIChE, APS, ACS, MRS, SFB, BMES, AIMBE, CRS, AAPS, and ASEE. Hehas supervised the research of more than 100PhDs and about 180 postdocs and graduate students. Peppas holds a Dipl. Eng.from the NTU ofAthens (1971), a Sc.D.from MIT (1973), and honorary doctorates from the Universities of Ghent, Parma,Athens, Ljubljana and Patras, andhonorary professorships from Sichuan University and Peking Union MedicalCollege.
Advanced solutions of a number of biomedical engineering problems requirethat nanotechnology, advanced biomaterials and molecular biology be used in asynergestic way to achieve targeted, effective vehicle for disease treatment.Engineering the molecular design of intelligent gels/biomaterials bycontrolling structure, recognition and specificity is the first step incoordinating and duplicating complex biological and physiologicalprocesses.Recent developments in siRNAand protein delivery have been directed towards the preparation of targetedformulations for protein delivery to specific sites, use ofenvironmentally-responsive polymers to achieve pH- or temperature-triggereddelivery, usually in modulated mode, and improvement of the behavior of their mucoadhesivebehavior and cell recognition.Weaddress design and synthesis characteristics of novel crosslinked networkscapable of protein release as well as artificial molecular structures capableof specific molecular recognition of biological molecules. Molecular imprintingand microimprinting techniques, which create stereo-specific three-dimensionalbinding cavities based on a biological compound of interest can lead topreparation of biomimetic materials for intelligent drug delivery, drug targeting,and tissue engineering. We have been successful in synthesizing novel glucose-and protein-binding molecules based on non-covalent directed interactionsformed via molecular imprinting techniques within aqueous media. We have alsodeveloped structurally superior materials to serve as effective carriers forsiRNA delivery to combat Crohn disease and ulcerative colitis.